Trial Profile

Sintilimab Combined with IBI310 and Surufatinib for the Treatment of High-grade Advanced-neuroendocrine Neoplasms: a Single Arm, Open-label, Multi Center, Phase II Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Sintilimab (Primary) ; Surufatinib (Primary)
Indications Neuroendocrine carcinoma; Neuroendocrine tumours
Focus Therapeutic Use
Acronyms NESSIE

Most Recent Events

14 Mar 2025 Planned number of patients changed from 40 to 30.
14 Mar 2025 Planned End Date changed from 1 Mar 2025 to 1 Sep 2025.
14 Mar 2025 Planned primary completion date changed from 1 Mar 2024 to 1 Sep 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com